New Director's Experience a Plus for MSU, but his Controversial Views Concern Some
By Matthew Miller,
Lansing State Journal
| 10. 06. 2012
Stephen Hsu was an unconventional choice to lead Michigan State University’s research enterprise.
A theoretical physicist by training, Hsu has done respected work on dark energy, black holes and the more esoteric reaches of particle physics, but his only experience in academic administration was a stint last year as the director of the University of Oregon’s Institute for Theoretical Science. The institute’s budget that year was just shy of $74,000.
As vice president for research and graduate studies at MSU, the position he assumed in August, Hsu is charged with setting the broad direction and expectations for a research operation that topped $400 million in expenditures in 2010. His office administers millions in internal grant money, ensures the university’s compliance with ethical and legal standards for research, leads MSU’s efforts to commercialize its research.
But Hsu has another sort of experience that MSU’s leaders found compelling: years as a Silicon Valley entrepreneur, and a successful one at that.
MSU President Lou Anna Simon said Hsu is not only “an extraordinary intellect,” but he “understands the relationship of research to economic...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...